Blueprint Medicines Reports Fourth Quarter and Full Year 2019 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Needham Starts NeoVolta (NEOV) at Buy
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Blueprint Medicines (BPMC) Tops Q4 EPS by 34c
February 13, 2020 7:24 AM ESTBlueprint Medicines (NASDAQ: BPMC) reported Q4 EPS of ($1.35), $0.34 better than the analyst estimate of ($1.69). Revenue for the quarter came in at $51.5 million versus the consensus estimate of $26.07 million.
For earnings history and earnings-related data on Blueprint Medicines (BPMC) click here.
... More